Daniel Garner Email & Phone Number

Salt Lake City, UT, US

Albuquerque, NM, US

Leading expansion of preclinical services for drug development companies across the Eastern US. Specializing in inhalation toxicology, infectious disease, gene therapy toxicology, bioanalytical, and general toxicology.

Vineyard, UT, US

• Built a ground up business development strategy with a pipeline of at least $30m in deals in only 2 months.
• Established relationships with key decision makers at multiple multinational chemical companies and managed the sales motion/technical details of progressing deals.
• Owned strategy for internal collaborations between commercialization and product development teams.

Salt Lake City, Utah, US

• Established a deal pipeline for antimicrobial products with large pharmaceutical companies and investors across the globe. Book of business pipeline over $50m with 10-25 companies at any time.
• Increased number of co-development partnerships with medical device and materials companies by 500% with a pipeline value up over $100m in progressing deals.
• Directed a cross-disciplinary, nimble, product development team of scientists with a $1.2m annual budget.

Salt Lake City, Utah, US

• Drove introductions, meetings, and client relations with potential business partners, fostering key connections for EVŌQ nano.
• Acted as the regulatory liaison with EPA and FDA, ensuring compliance and smooth communication with governing bodies.
• Led market research activities to identify target markets, competitors, and potential partners, contributing to strategic decision-making.
• Spearheaded non-dilutive funding efforts, securing SBIR, foundation, federal, and state government grants to support company growth.

Salt Lake City, Utah, US

• Project lead for crucial studies resulting in partnerships for ExpeDRY Products.
• Managed regulatory strategy and communications with partner companies.
• Owned regulatory strategy and relationships with the EPA and FDA for key products.

• Built business development strategies and portfolios for antibody drug conjugates leading to a pipeline of deals valued over $100m.
• Raised over $1,000,000 from angel and family offices for preclinical development.
• Owned strategy and execution for study design, manufacture, and regulatory affairs for pre-clinical lead assets.
• Drove non-dilutive funding efforts, including NIH SBIR, foundation, federal, and state government grant applications.

• Co-led pre-clinical strategy for non-invasive oral anesthetics.
• Helped build go-to-market strategy for new products.
• Supported regulatory strategy for non-invasive oral anesthetics.

Bachelor'S Degree, Biotechnology

Minor, Theatre/Theater